Press Releases

 
Press Releases
  Date Title View
Oct 11, 2016
CAMBRIDGE, Mass., Oct. 11, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced final results from the pivotal Phase 3 NAPOLI-1 study validating the use of ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin, which represents a new standard of care for patients with met...
Oct 3, 2016
CAMBRIDGE, Mass., Oct. 3, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced a major corporate restructuring with the objective of prioritizing its research and development on a focused set of systems biology-derived oncology products and strengthening its financial runway.  As part of this move, Merrimack is immedi...
Sep 28, 2016
CAMBRIDGE, Mass., Sept. 28, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced it will present six posters from its systems-biology derived antibody engineering and nanotherapeutic portfolios at the European Society for Medical Oncology (ESMO) 2016 Congress, October 7 - 11, 2016 in Copenhagen, Denmark.   Merr...
Aug 4, 2016
CAMBRIDGE, Mass., Aug. 4, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its second quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Thursday, August 4 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results. ...
Jul 25, 2016
CAMBRIDGE, Mass., July 25, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for ONIVYDE® (irinotecan liposome injection), also known as "nal-IRI", in combination with fluorouraci...
Jul 19, 2016
CAMBRIDGE, Mass., July 19, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK)  today announced that the company will host its Second Quarter 2016 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Thursday, August 4.    The call will cover an update on Merrimack's progress as well as a summary of second quar...
Jul 6, 2016
CAMBRIDGE, Mass., July 6, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted seribantumab, also known as MM-121, Fast Track designation for development in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) w...
Jun 30, 2016
CAMBRIDGE, Mass., June 30, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced a newly presented analysis of the Phase 3 NAPOLI-1 data shows patients treated with ONIVYDE® (irinotecan liposome injection), also known as "nal-IRI," in combination with fluorouracil (5-FU) and leucovorin, maintain similar baseline q...
Jun 21, 2016
CAMBRIDGE, Mass., June 21, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present new analyses of the Phase 3 NAPOLI-1 data in an oral presentation and poster discussion session at the European Society for Medical Oncology  (ESMO) 18th World Congress on Gastrointestinal Cancer, June 29 - July 2, 201...
Jun 6, 2016
CAMBRIDGE, Mass., June 6, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor, in patients with refractory solid tumors. These results were presented at a Poster Discus...
FirstPrevious
2
...
NextLast
= add release to Briefcase

In this section, you will find several of Merrimack’s high-resolution images. All images here are copyrighted by Merrimack Pharmaceuticals, Inc., and are made available here for editorial use only. By downloading and/or using any of the Merrimack’s images, you acknowledge the rights of Merrimack’s images, and you agree to comply with the usage guidelines.

X

Accept | Decline